Research programme: embryonic stem cell therapeutics - CHA Biotech
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator CHA Biotech
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in South Korea
- 08 Jan 2007 Preclinical trials in Huntington's disease in South Korea (unspecified route)